An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2
/in Breast Cancer, International PublicationsAntigen crosspresentation by human plasmacytoid dendritic cells
/in HIV/AIDS, International PublicationsTargeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine
/in Hypernephroma, International PublicationsCombined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study
/in Hypernephroma, International PublicationsUse of reverse genetics to enhance the oncolytic properties of Newcastle disease virus
/in International Publications, Newcastle Disease VirusComparison of dendritic cell-mediated immune responses among canine malignant cells
/in International Publications, Malignant LymphomaLarge-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia
/in Acute Leukemia, International PublicationsComparison of intratumor and intraluminal temperatures during locoregional deep hyperthermia of pelvic tumors
/in Cervical Cancer, International PublicationsMonocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile
/in Chronic Virus Hepatitis, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer